The meaning of CHRONIC MYELOGENOUS LEUKEMIA is myelogenous leukemia that is marked by an abnormal increase in mature and immature granulocytes (as neutrophils, eosinophils, and myelocytes) especially in bone marrow and blood, that is characterized by fat
The meaning of CHRONIC MYELOGENOUS LEUKEMIA is myelogenous leukemia that is marked by an abnormal increase in mature and immature granulocytes (as neutrophils, eosinophils, and myelocytes) especially in bone marrow and blood, that is characterized by fat
Chronic myeloid leukemia (CML) is a relatively rare form of leukemia, comprising 15% of all leukemia cases. According to the National Cancer Institute 's Surveillance Epidemiology and End Result (SEER) Cancer Statistics database, an estimated 2,800 men and 2,070 women will be diagnosed with ...
Chronic myelogenous leukemia (CML), also known as chronic myeloid leukemia, is a myeloproliferative disorder characterized by increased proliferation of the granulocytic cell line without the loss of their capacity to differentiate. It accounts for 20% o
chronic myeloid leukemia 美 英 un.慢性粒细胞性白血病 英汉 un. 1. 慢性粒细胞性白血病
Leukemia--Chronic Myeloid ( Myelogenous )
Chronic myeloid leukemia (CML) is defined as the clonal myeloproliferative disorder characterized by the expression of BCR-ABL fusion gene produced by reciprocal translocation of Philadelphia chromosome. From: European Journal of Medicinal Chemistry, 2021 ...
Chronic myeloid leukemia (CML) is caused by BCRABL1 in a cell with the biological potential, intrinsic or acquired, to cause leukemia. This cell is commonly termed the CML leukemia stem cell (LSC). In humans a CML LSC is operationally-defined by ≥1 in v
W. The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage. Ann. Hematol. 79, 424–431 (2000). Article CAS PubMed Google Scholar ...
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. Imatinib therapy, which targets the oncogene product BCR-ABL, has transformed chronic myeloid leukemia (CML) from a life-threatening disease into a chronic... Corbin,S Amie,Agarwal,... -...